Mortality Risks in New-Onset Childhood Epilepsy

WHAT’S KNOWN ON THIS SUBJECT: Seizure-related death, including sudden death, is a frightening prospect. In part because risk and prevention are poorly understood, neurologists tend to avoid discussions of sudden death with families and young patients.

WHAT THIS STUDY ADDS: Most deaths in children with epilepsy are not seizure related. Relative to the population, however, sudden and seizure-related deaths alone double overall mortality. In uncomplicated epilepsy, such deaths occur at rates comparable to individual leading causes of death in young people.

OBJECTIVES: Estimate the causes and risk of death, specifically seizure related, in children followed from onset of epilepsy and to contrast the risk of seizure-related death with other common causes of death in the population.

METHODS: Mortality experiences from 4 pediatric cohorts of newly diagnosed patients were combined. Causes of death were classified as seizure related (including sudden unexpected death [SUDEP]), natural causes, nonnatural causes, and unknown.

RESULTS: Of 2239 subjects followed up for >30,000 person-years, 79 died. Ten subjects with lethal neurometabolic conditions were ultimately excluded. The overall death rate (per 100,000 person-years) was 228; 743 in complicated epilepsy (with associated neurodisability or underlying brain condition) and 36 in uncomplicated epilepsy. Thirteen deaths were seizure-related (10 SUDEP, 3 other), accounting for 19% of all deaths. Seizure-related death rates were 43 overall, 122 for complicated epilepsy, and 14 for uncomplicated epilepsy. Death rates from other natural causes were 159, 561, and 9, respectively. Of 48 deaths from other natural causes, 37 were due to pneumonia or other respiratory complications.

CONCLUSIONS: Most excess death in young people with epilepsy is not seizure-related. Mortality is significantly higher compared with the general population in children with complicated epilepsy but not uncomplicated epilepsy. The SUDEP rate was similar to or higher than sudden infant death syndrome rates. In uncomplicated epilepsy, sudden and seizure-related death rates were similar to or higher than rates for other common causes of death in young people (eg, accidents, suicides, homicides). Relating the risk of death in epilepsy to familiar risks may facilitate discussions of seizure-related mortality with patients and families. Pediatrics 2013;132:124–131

AUTHORS: Anne T. Berg, PhD,a Katherine Nickels, MD,b Elaine C. Wirrell, MD,c Ada T. Geerts, PhD,d Petra M.C. Callenbach, PhD,e Willem F. Arts, MD, PhD,c Christina Rios, BA,f Peter R. Camfield, MD, and Carol S. Camfield, MDf

4Epilepsy Center, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, Illinois; 5Epilepsy and Child and Adolescent Neurology, Mayo Clinic, Rochester, Minnesota; 6Neurology, Erasmus Medical Center, Rotterdam, Netherlands; 7Neurology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands; 8Pediatrics, Yale Medical School, New Haven, Connecticut; and 9Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada

KEY WORDS
children, epilepsy, mortality, SUDEP

ABBREVIATIONS
CI—confidence interval
PY—person-years
SIDS—sudden infant death syndrome
SUDEP—sudden unexpected death in epilepsy

Dr Berg is principal investigator for the Connecticut Study of Epilepsy, planned and conducted the pooled analysis, and drafted the initial manuscript; Dr Nickels is the lead author on the Rochester study, provided follow-up time and characterized patient deaths and seizure outcomes, and participated in reviewing the manuscript; Dr Wirrell is the senior investigator of the Rochester study, contributed to conceptualizing the analysis, participated in review of medical charts to define epilepsy variables and characterize patient deaths, and participated in reviewing the manuscript; Dr Geerts is 1 of the lead authors from the Dutch study, provided follow-up time information and information about causes of death, and participated in revision of the manuscript; Dr Arts is 1 of the senior investigators of the Dutch study, provided review of causes of death, and participated in revision of the manuscript; Ms Rios is the project coordinator for the Connecticut study, developed and executed the approaches for ascertaining death and causes of death, and participated in reviewing the manuscript; Dr P.R. Camfield is a co-principal investigator for the Nova Scotia study, provided additional information about the Nova Scotia study, reviewed causes of death, and participated in reviewing the manuscript; and Dr C.S. Camfield is a co-principal investigator for the Nova Scotia study, provided additional information about the Nova Scotia study, critiqued the approach, and participated in revising the manuscript. All authors read and approved the submitted version.

(Continued on last page)
Mortality rates in people with epilepsy are 2 to 4 times higher overall\(^5\)–\(^7\) and 5 to 10 times higher in pediatric epilepsy.\(^5\)–\(^8\) This increased risk occurs for several reasons: (1) lethal neurometabolic conditions that present with epilepsy; (2) systemic complications associated with neurodisability; (3) indirect factors resulting in higher mortality (eg, suicide); and (4) deaths shown or presumed to be directly due to the occurrence of a seizure. This last group includes sudden unexpected death in epilepsy (SUDEP), which has been the center of an international awareness campaign\(^10\) and many conferences, as well as the focus of several grant initiatives. Although increasing evidence is clarifying the sequence of events leading to SUDEP, many of which may have implications for prevention, there is still a reticence among neurologists to raise the subject of SUDEP with patients and families. A summary of the National Institutes of Neurologic Disorders and Stroke conference on SUDEP highlighted the importance of conveying information to families and patients about the risk of death in general and SUDEP in particular.\(^11\) Concerns were expressed that these discussions might cause anxiety or depression and that there is a need to distinguish between “low” risk and “no” risk. Further research was suggested to determine how best to provide information about SUDEP and how to overcome the reluctance of health professionals to present this information. This reluctance stands in sharp contrast to the situation in pediatrics, where pediatricians are trained and provide professional support in discussing these risks with parents beginning with the risk of sudden infant death syndrome (SIDS).\(^12\)

One barrier in discussing SUDEP or seizure-related death is the paucity of data on which to base an accurate risk estimate, particularly in children and most especially at the time of initial diagnosis when the topic might reasonably first be raised. This lack of data exists in part because the risk is statistically very low and thus hard to determine in a single study. To address this knowledge gap, we pooled data from 4 large pediatric cohorts to obtain direct estimates of the mortality risk overall and from specific causes of mortality, particularly seizure related and SUDEP.

**METHODS**

The authors of 4 published pediatric cohort studies combined data regarding mortality.\(^5\)–\(^8\) Methods for each study are outlined in Table 1. For 1 study, results are updated here from an earlier report based on an additional 8 years of follow-up.\(^5\)

Deaths were ascertained systematically within each study. Methods included report of parents to study staff during scheduled follow-up calls; report of treating physicians to study staff;\(^6\)–\(^8\), review of national death indices, health registries, and other administrative databases depending on the study\(^6\)–\(^8\), and an active population-based surveillance program.\(^5\) Epilepsy in association with lethal neurometabolic or neurodegenerative conditions was explicitly excluded from 1 study.\(^7\) To be consistent, children with such conditions were excluded from the other 3 studies for these analyses.

Epilepsy presentation was considered “complicated” if there was a known structural brain lesion, significant intellectual disability, or abnormal result on neurologic examination; it was considered “uncomplicated” if these factors were absent.\(^5\)–\(^8\) Children with autism generally had intellectual disability and were thus included in the complicated group. For 1 study, the distinction was based solely on the absence or presence of cognitive or neurologic disability.\(^7\) This information was extracted from the medical records as recorded by the child’s treating neurologist. In 1 study, research MRIs and neurocognitive testing were performed in more than one-half of the cohort,\(^5\) and the results were used to

---

**TABLE 1** Description of 4 Studies

<table>
<thead>
<tr>
<th>Variable</th>
<th>Nova Scotia(^7)</th>
<th>Netherlands(^5)(^8)</th>
<th>Connecticut(^6)</th>
<th>Rochester(^3)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Methods and patient source</strong></td>
<td>Prospective, population based</td>
<td>Prospective, regional</td>
<td>Prospective, community based</td>
<td>Retrospective, population based</td>
</tr>
<tr>
<td><strong>Inclusion criteria</strong></td>
<td>Newly diagnosed epilepsy; (\geq 2) unprovoked seizures; Evidence of progressive neurologic disease was grounds for exclusion</td>
<td>Newly diagnosed epilepsy; (\geq 2) unprovoked seizures</td>
<td>Newly diagnosed epilepsy; (\geq 2) unprovoked seizures</td>
<td>Newly diagnosed epilepsy; (\geq 2) unprovoked seizures or single seizure with brain injury and treatment initiated</td>
</tr>
<tr>
<td><strong>Age at onset</strong></td>
<td>1 mo–16 y Mean ± SD: 6.2 ± 4.5 y</td>
<td>1 mo–16 y Mean ± SD: 5.6 ± 4.1 y 5.3–33.5 y</td>
<td>1 mo–16 y Mean ± SD: 5.8 ± 4.0 y 14.5–35.0 y</td>
<td>1 mo–17 y Mean ± SD: 6.9 ± 5.1 y 0.2–45.4 y</td>
</tr>
<tr>
<td><strong>Age at time of analysis in survivors</strong></td>
<td>Mean: 19.2 y</td>
<td>Mean ± SD: 20.7 ± 4.7 y</td>
<td>Mean ± SD: 23.3 ± 4.3 y</td>
<td>Mean ± SD: 16.7 ± 9 y</td>
</tr>
<tr>
<td><strong>Age at death</strong></td>
<td>0.5–30 y Mean ± SD: 12.0 ± 7.3 y</td>
<td>2.1–26.9 y Mean ± SD: 11.8 ± 7.5 y</td>
<td>1.8–28.7 y Mean ± SD: 11.2 ± 8.8 y</td>
<td>0.2–21.7 y Mean ± SD: 8.2 ± 6.5 y</td>
</tr>
<tr>
<td><strong>Ascertainment of deaths</strong></td>
<td>Provincial health registry and other clinical sources</td>
<td>Physician report to study, national health records</td>
<td>Family report to study, Social Security Death Index</td>
<td>Rochester Epidemiology Project surveillance system</td>
</tr>
</tbody>
</table>
supplement clinical assessment. Person-years (PY) of follow-up were calculated for each patient as the time from study entry (diagnosis) to either death or, for survivors, date of last contact (Table 1).

All studies obtained copies of death certificates and, if performed, copies of autopsy reports. In some instances, eye witness accounts or emergency department or in-patient reports from terminal visits or hospitalizations were available and contributed to assignment of cause of death. Information about cause of death was compiled from death certificates, autopsy reports, and other medical records. Collaborating investigators reviewed the information, and a consensus was reached on how to best categorize each death.

Causes of death were grouped as SUDEP, other seizure related, other natural, and nonnatural (Table 2). In the absence of any information, the cause of death was characterized as unknown. SUDEP was further categorized into definite, probable, and possible SUDEP according to recent recommendations. In children with significant neurologic compromise, we considered an otherwise unexplained sudden death attributed to cardiac or cardiopulmonary arrest to be possible (not probable) SUDEP in the absence of an autopsy report that definitively excluded infections or other sources of airway compromise.

Death rates with 95% confidence intervals (CIs) are reported as number per 100 000 PY and were calculated by using standard techniques. Poisson regression was performed in SAS Proc Genmod (SAS version 9.2, SAS Institute, Inc, Cary, NC) to test for differences between studies and between complicated and uncomplicated epilepsy. We performed sensitivity analyses to examine the impact of the following: (1) counting possible SUDEP as seizure related; and (2) counting unknown cause as being seizure related or even SUDEP. For approximate comparisons, death rates in the first 3 decades of life from the 3 countries in which the studies were performed were obtained from vital statistics registries in each country. All procedures were approved by the ethics committees at all participating institutions. The Connecticut, Dutch, and Canadian studies obtained written informed consent for participation in the original studies. The Rochester Epidemiology Project functions under a community consent protocol.

**RESULTS**

The 3 studies included 2239 patients with childhood-onset epilepsy (onset ≤16 years of age) or ≤17 years of age). Ten children with lethal metabolic conditions (2, Menkes kinky hair disease; 4, neuronal ceroid lipofuscinoses; 1, Zellweger syndrome; 2, mitochondrial disorders; 1, Niemann-Pick disease) were excluded from further consideration.

The remaining 2229 subjects were followed for a total of 30 284 PY, and 69 deaths occurred (14–26 per study). The crude death rate per 100 000 PY for all subjects combined was 228 (95% CI: 174–282). Point estimates of the crude rates varied somewhat among the 4 studies, but their CIs overlap (Table 3). A formal test of these differences indicated that they were not overall statistically significant. Within complicated and uncomplicated groups, these differences were greatly reduced. Data adequately fit assumptions for a Poisson distribution.

The death rate in the complicated group (743 [95% CI: 557–930]) was substantially higher than in the uncomplicated group (56 [95% CI: 11–61]) (P < .0001).

**Causes of Death**

Ten deaths were attributed to SUDEP (5 definite with autopsy confirmation, 3 probable, and 2 possible). Three seizure-related deaths occurred (1 status epilepticus, 1 iatrogenic complications
from treatment of status epilepticus, and 1 aspiration during a seizure). Other natural causes accounted for 48 deaths (pneumonia \( n = 35 \), sepsis \( n = 3 \), ventriculoperitoneal shunt malfunction \( n = 3 \), tracheotomy malfunction \( n = 1 \), pulmonary embolism \( n = 1 \), cerebral hemorrhage \( n = 2 \), cancer \( n = 2 \), and cardiomyopathy \( n = 1 \)). Five deaths were due to nonnatural causes (2 nonseizure-related accidents, 2 suicides, and 1 homicide). No information was available regarding cause of death for the remaining 3 individuals.

Death rates according to types of cause were calculated overall and for complicated and uncomplicated presentations (Table 4). For potentially seizure-related deaths, we calculated rates for SUDEP \( n = 10 \), definite and probable SUDEP \( n = 8 \), all seizure-related death \( n = 13 \) [10 SUDEP and 3 other], and seizure-related deaths plus unknown \( n = 16 \) [SUDEP, other seizure-related, and unknown]). All causes of death were substantially higher in the complicated group compared with the uncomplicated group. The rate of seizure-related deaths in the complicated group (122 per 100 000 PY) was multiples of the total population death rates in the first 3 decades of life and higher than SIDS rates in developed countries (Table 5). The comparable figure for the uncomplicated group (14 per 100 000 PY) was in the same range as or slightly higher than the single leading causes of death for young people in the population (depending on the country), at the low end of the range for SIDS in developed countries, and higher than 1 estimate of sudden death in the 1- to 30-year-olds.

### Patient Profiles Associated With Mortality

Deaths occurred on average 7.5 (± 4.9) years after diagnosis (Table 6). In the complicated group, there was a moderate trend suggesting that older onset was associated with a longer time to death (Fig 1).

Average age at death was 11.6 years and was similar across most causes of death. Male and female subjects were approximately equally represented across cause of death categories. Given the small numbers involved, formal tests were not conducted. Data are presented for descriptive purposes only.

Most of the deaths \( n = 61 \) (88%) occurred in participants with complicated presentations, and almost all of these individuals had mild \( n = 5 \) or more severe \( n = 51 \) cognitive impairment. Drug resistance (57%), lack of seizure freedom in the past year (74%), and a history of convulsive seizures (68%) and of status epilepticus (48%) were all more common than reported for these cohorts in previous publications.\(^5\)\(^6\)\(^9\) No seizure-related deaths occurred in children with the generally pharmacoresponsive and often self-limited syndromes such as childhood absence epilepsy or benign Rolandic epilepsy. Two accidental deaths occurred; neither was seizure related.
**DISCUSSION**

Compared with death rates for 1- to 29-year-olds in the United States, Canada, and the Netherlands, the overall death rates in young people followed from their initial diagnosis of childhood-onset epilepsy were substantially elevated. Most of the excess risk occurred in association with complicated epilepsy presentations, particularly with neurologic and intellectual disability. The crude mortality rate in this group (743 per 100,000) exceeded recent reports for infant mortality rates in the same countries from which the cohorts came (Table 5). Most of the deaths were secondary to infections and complications from underlying neurologic disability, which by itself confers a substantial mortality risk.19–25 Prevention of such deaths, when possible, likely lies in the arena of long-term supportive care and infection control, not seizure management per se. Inclusion of 10 children with diagnosed neurometabolic syndromes with a known lethal course yielded a higher death rate overall (261 [95% CI: 203–318]), particularly in the complicated group (861 [95% CI: 661–1062]). As with the neurodisability group, prevention of deaths associated with these diseases has little to do with seizure management. Comparable to reports from other researchers,2,22,26 the death rate in the uncomplicated epilepsy group did not seem substantially greater than expected for the general population.

### TABLE 5

<table>
<thead>
<tr>
<th>Mortality Age Group or Cause</th>
<th>United States15</th>
<th>Canada16–17</th>
<th>The Netherlands18</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infant</td>
<td>630</td>
<td>510</td>
<td>439</td>
</tr>
<tr>
<td>SIDS</td>
<td>57</td>
<td>35</td>
<td>9</td>
</tr>
<tr>
<td>1- to 29-year-olds*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall</td>
<td>55</td>
<td>34</td>
<td>26</td>
</tr>
<tr>
<td>Accidental</td>
<td>24.6</td>
<td>14.2</td>
<td>7.0</td>
</tr>
<tr>
<td>Homicide</td>
<td>7.5</td>
<td>2.0</td>
<td>0.9</td>
</tr>
<tr>
<td>Suicide</td>
<td>6.8</td>
<td>6.9</td>
<td>3.0</td>
</tr>
<tr>
<td>Cancers</td>
<td>4.3</td>
<td>4.5</td>
<td>3.9</td>
</tr>
<tr>
<td>Heart/circulatory</td>
<td>3.2</td>
<td>2.5</td>
<td>1.9</td>
</tr>
</tbody>
</table>

Rates are given per 100,000 per year.

* Weighted average based on age-specific brackets.

### TABLE 6

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Overall (N = 69*)</th>
<th>SUDEP (n = 10)</th>
<th>Other Seizure Related (n = 5)</th>
<th>Other Natural (n = 48)</th>
<th>Nonnatural (n = 5)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median age at onset</td>
<td>2.0 y</td>
<td>2.7 y</td>
<td>4.6 y</td>
<td>1.3 y</td>
<td>12.0 y</td>
</tr>
<tr>
<td>IQR (minimum, maximum)</td>
<td>6 mo–7.0 y (1 mo–15.7 y)</td>
<td>1.3–11.8 y (1 mo–12.3 y)</td>
<td>0.3–3.7 y (1 mo–12y)</td>
<td>11.4–14.0 y (3.4–15.3 y)</td>
<td></td>
</tr>
<tr>
<td>Median age at death</td>
<td>11.0 y</td>
<td>13.7 y</td>
<td>7.8 y</td>
<td>8.3 y</td>
<td>18.2 y</td>
</tr>
<tr>
<td>IQR (minimum, maximum)</td>
<td>5–17 y (7 mo–30 y)</td>
<td>5.5–20 y (20–27.9 y)</td>
<td>5.0–15.8 y (7 mo–28.6 y)</td>
<td>18.0–19.2 y (13.9–30.0 y)</td>
<td></td>
</tr>
<tr>
<td>Median time to death</td>
<td>7.0 y</td>
<td>9.2 y</td>
<td>6.5 y</td>
<td>5.3 y</td>
<td>8.3 y</td>
</tr>
<tr>
<td>IQR (minimum, maximum)</td>
<td>3.2–11.7 y (5mo–20.2 y)</td>
<td>3.2–12.8 y (5mo–15.9 y)</td>
<td>1.3–6.9 y (8 mo–20.2 y)</td>
<td>2.8–11.6 y (8 mo–20.2 y)</td>
<td>7.5–10.4 y (4.0–14.5 y)</td>
</tr>
<tr>
<td>Gender, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>37 (54)</td>
<td>5 (50)</td>
<td>2 (67)</td>
<td>23 (48)</td>
<td>4 (80)</td>
</tr>
<tr>
<td>Female</td>
<td>32 (46)</td>
<td>5 (10)</td>
<td>1 (33)</td>
<td>45 (52)</td>
<td>1 (20)</td>
</tr>
<tr>
<td>Presentation of epilepsy, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Complicated</td>
<td>61 (88)</td>
<td>8 (80)</td>
<td>2 (67)</td>
<td>48 (96)</td>
<td>3 (60)</td>
</tr>
<tr>
<td>Uncomplicated</td>
<td>8 (12)</td>
<td>2 (20)</td>
<td>1 (33)</td>
<td>2 (4)</td>
<td>2 (20)</td>
</tr>
<tr>
<td>Cognitive level, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td>15 (18)</td>
<td>3 (30)</td>
<td>1 (33)</td>
<td>4 (8)</td>
<td>4 (80)</td>
</tr>
<tr>
<td>Mildly impaired</td>
<td>5 (7)</td>
<td>3 (30)</td>
<td>1 (33)</td>
<td>1 (2)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Moderately/severely impaired</td>
<td>51 (74)</td>
<td>4 (40)</td>
<td>1 (33)</td>
<td>43 (90)</td>
<td>1 (20)</td>
</tr>
<tr>
<td>Type of epilepsy, n</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonsyndromic-focal</td>
<td>33</td>
<td>6</td>
<td>3</td>
<td>19</td>
<td>4</td>
</tr>
<tr>
<td>Nonsyndromic-generalized, mixed</td>
<td>20</td>
<td>1</td>
<td>0</td>
<td>17</td>
<td>0</td>
</tr>
<tr>
<td>West, LGS, Ohtahara, Dravet syndromes</td>
<td>13</td>
<td>3</td>
<td>0</td>
<td>10</td>
<td>0</td>
</tr>
<tr>
<td>Other</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Drug resistance, n (%)</td>
<td>39 (57)</td>
<td>6 (60)</td>
<td>3 (100)</td>
<td>27 (56)</td>
<td>3 (60)</td>
</tr>
<tr>
<td>Epilepsy surgery, n (%)</td>
<td>3 (4)</td>
<td>2 (20)</td>
<td>0 (0)</td>
<td>1 (2)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Seizure in last year, n (%)</td>
<td>51 (74)</td>
<td>9 (90)</td>
<td>3 (100)</td>
<td>34 (71)</td>
<td>3 (60)</td>
</tr>
<tr>
<td>Convolusions, n (%)</td>
<td>47 (68)</td>
<td>9 (50)</td>
<td>3 (100)</td>
<td>31 (65)</td>
<td>3 (60)</td>
</tr>
<tr>
<td>Status epilepticus, n (%)</td>
<td>33 (48)</td>
<td>5 (50)</td>
<td>3 (100)</td>
<td>24 (50)</td>
<td>1 (20)</td>
</tr>
</tbody>
</table>

A version of this table with CIs is available online as Supplemental Information. For seizure control, an indicator for <1 versus ≥1 year seizure-free at time of death or at last contact was adopted because this factor could be accurately applied in all patients given the variability in coding of information across studies. Pharmacoresistance was defined fairly consistently across the studies with only minor variations. All studies required failure of at least 2 or 3 medications to meet the criteria for pharmacoresistance. IQR, interquartile range; LGS, Lennox-Gastaut syndrome.

* Three subjects with unknown causes are not included beyond the overall summary information.
Sudden death is of particular concern for people with epilepsy and their families. In young adults (aged 20–40 years), the rate of sudden death in people with epilepsy is estimated to be 24 times that seen in the general population. The crude death rate from SUDEP alone in our combined series (33 per 100,000 PY overall and 26 per 100,000 PY for definite/probable SUDEP) is similar to the total population death rate in the first 2 decades of life (excluding infancy) (Table 6). In participants with complicated presentations, however, the SUDEP rate was 2 to 3 times the overall death rates seen in the general population. In fact, others have found a preponderance of SUDEP in association with complicated epilepsy.

In young people with uncomplicated epilepsy, the death rates from SUDEP (9 per 100,000 PY) and all seizure-related deaths (14 per 100,000 PY) are comparable to the leading cause of death (accidents) and higher than other common causes of death, including homicide, suicide, cancer, and heart disease (Table 5). Our estimated SUDEP and seizure-related death rates are in the same range as SIDS death rates in developed countries (9 per 100,000 [Japan] to 80 per 100,000 [New Zealand]).

Our point estimates, even for uncomplicated epilepsy, are greater than the rate for all sudden deaths reported in the Netherlands in 1- to 30-year-olds (2.26 per 100,000 PY). SUDEP risk is age related and is higher in adults, both in adult-onset epilepsy and in adults with childhood-onset epilepsy. No firm data are available, but anecdotal reports and identified risk factors suggest that the transition time for adolescents and young adults, who may not fully understand the importance of good sleep and nutrition patterns, avoidance of excess alcohol and use of drugs, and adherence to prescribed treatment for preventing seizures, may pose some risks that could be modified. Transition from pediatric to adult care is complicated and particularly so in children with chronic neurologic conditions.

Somewhat less appreciated is that SUDEP also occurs in infants and young children. A recent survey of parents whose children had Dravet syndrome reported a series of 31 deaths, 19 of which were attributed to SUDEP. The majority of the children were aged <5 years at the time of their deaths. Current thinking suggests there is a spectrum of sudden death in the very young beginning with SIDS, of which SUDEP may be a part and which involves a variety of mechanisms including brainstem serotonergic dysfunction and heart channelopathies. Whether mechanisms involved in SUDEP in very young children differ from those in older individuals is under investigation.

The absence of definite seizure-related accidental deaths was encouraging. Potentially, the 3 deaths for which the causes were unknown could have been due to seizure-related accidents; however, including these 3 deaths still places an upper limit on such deaths in our combined cohorts. The low or absent risks we observed in no way indicate that the potential risks are not real. We speculate that common sense measures to prevent seizure-related accidents and accidental deaths in young persons may be having an impact.

The suicide rate was also comparable to that in the general population. Our estimate could be higher if any of the deaths with unknown causes were due to suicide. Relationship to medication use was not available in all studies; however, as reviewed elsewhere, the risks associated with uncontrolled seizures far outweigh the risk of suicide and any potential increased risk of suicide associated with medication use, a risk that has largely been disproven.

Our study has several advantages. We assembled perhaps the largest series of population-representative pediatric epilepsy patients followed from initial diagnosis for 10 years. All studies had systematic approaches to defining entry criteria and targeted the same age-at-onset range. All studies had systematic approaches to determine that a death had occurred and obtained death certificates and, when available, autopsy reports. Hospital records and eye witness accounts were also reviewed when available. We used the recent recommendations on SUDEP definitions and determined
the level of certainty regarding that designation.13
There are inevitable weaknesses. Studies were performed in different populations during largely non-overlapping time periods. We were not able to combine data at an individual level because files were no longer available for 1 study. We could not make precise comparisons with population death rates because studies were performed in different countries and over different time periods. However, such comparisons are always approximate. We present them to place our mortality findings in a larger context.

Unlike SIDS, for which there has been a major public health campaign aimed at providers and parents and advanced through the American Academy of Pediatrics12 and other organizations, discussion of SUDEP still seems to encounter a certain reluctance on the part of neurologic care providers.11 Parents, however, generally do want to be informed of these risks,41 and parents who have lost children wish they had been offered such information.10 Although this reluctance and unease among neurologists will surely change,42 it seems that pediatricians who have overcome the barriers of discussing such risks with their families and young patients might be well positioned, if provided with reasonable information about SUDEP, to broach these topics and to address parents’ concerns. Ways of preventing SUDEP are unclear and not as advanced as with SIDS. The main risk factor for SUDEP is lack of seizure control, which highlights the importance of adherence to recommended medication schedules.43,44 Children with seizures during sleep may also be at increased risk depending on their epilepsy and seizure type, and families may benefit from discussion about this particular concern. Reasonable supervision and precautions may also mitigate some of the risk.45 These issues can be emphasized with parents of young children with epilepsy as well as with adolescents acquiring greater autonomy and transitioning to adult care.35

CONCLUSIONS
Most mortality in young people with epilepsy is secondary to factors associated with neurodisability. Sudden and other seizure-related death does occur at rates higher than in the general population, although most of the risk occurs in association with complicated epilepsy. Demystifying the risk by measuring it and placing it in the context of other risks of childhood death faced by all parents may facilitate discussion of seizure-related death. Pediatricians may benefit those families who have a child with epilepsy by discussing these issues frankly. Generally, they can offer reassurance regarding the actual magnitude of the risk. Providing families with such information as well as an understanding of the importance of medication adherence and other common sense measures is a role appropriate for primary care providers.

REFERENCES


35. Langian T, Nashef L, Sander JW. Case-control study of SUDEP. *Neurology*. 2005;64(7):1131–1133


(Continued from first page)

www.pediatrics.org/cgi/doi/10.1542/peds.2012-3998
doi:10.1542/peds.2012-3998

Accepted for publication Mar 21, 2013

This work was presented in preliminary form at the Partners Against Mortality in Epilepsy conference, June 22–24, 2012; Evanston, Il. It was also presented at the American Epilepsy Society meeting, November 30–December 4, 2012, San Diego, CA.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Address correspondence to Anne T. Berg, PhD, Epilepsy Center, Ann & Robert H. Lurie Children’s Hospital of Chicago, 225 East Chicago Ave, Box 29, Chicago, IL 60611. E-mail: atberg@luriechildrens.org

© 2013 by the American Academy of Pediatrics

**FINANCIAL DISCLOSURE:** Dr Berg has received speaker honoraria and travel support from Bial and Medical University of South Carolina and travel support from the International League Against Epilepsy serves on advisory boards for the National Institutes for Research in Epilepsy and Esai, serves on the editorial boards of Epilepsy & Behavior and Neurology, and is supported by funding from the National Institute of Neurological Disorders and Stroke (grant R37-NS31148) and the Pediatric Epilepsy Research Foundation. Dr Callenbach received an unrestricted research grant from UCB Pharma B.V. Drs Nickel and Wirrell were supported in this work by a Mayo Foundation CR20 Award. In addition, the research reported in this publication was supported by the National Institute on Aging of the National Institutes of Health under...
Mortality Risks in New-Onset Childhood Epilepsy
Anne T. Berg, Katherine Nickels, Elaine C. Wirrell, Ada T. Geerts, Petra M.C. Callenbach, Willem F. Arts, Christina Rios, Peter R. Camfield and Carol S. Camfield
Pediatrics 2013;132;124; originally published online June 10, 2013;
DOI: 10.1542/peds.2012-3998

Updated Information & Services
including high resolution figures, can be found at:
/content/132/1/124.full.html

Supplementary Material
Supplementary material can be found at:
/content/suppl/2013/06/05/peds.2012-3998.DCSupplemental.html

References
This article cites 39 articles, 10 of which can be accessed free at:
/content/132/1/124.full.html#ref-list-1

Citations
This article has been cited by 6 HighWire-hosted articles:
/content/132/1/124.full.html#related-urls

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
Neurology
/cgi/collection/neurology_sub
Neurologic Disorders
/cgi/collection/neurologic_disorders_sub

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
/site/misc/Permissions.xhtml

Reprints
Information about ordering reprints can be found online:
/site/misc/reprints.xhtml
Mortality Risks in New-Onset Childhood Epilepsy
Anne T. Berg, Katherine Nickels, Elaine C. Wirrell, Ada T. Geerts, Petra M.C. Callenbach, Willem F. Arts, Christina Rios, Peter R. Camfield and Carol S. Camfield
Pediatrics 2013;132:124; originally published online June 10, 2013;
DOI: 10.1542/peds.2012-3998

The online version of this article, along with updated information and services, is located on the World Wide Web at:
/content/132/1/124.full.html